Septerna (NASDAQ:SEPN - Get Free Report) is projected to release its Q1 2025 earnings data on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.
Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $0.22 million during the quarter. On average, analysts expect Septerna to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Septerna Stock Performance
NASDAQ:SEPN traded down $0.02 during midday trading on Friday, reaching $10.47. The stock had a trading volume of 967,475 shares, compared to its average volume of 697,639. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The firm's fifty day simple moving average is $8.47 and its 200-day simple moving average is $11.70.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on SEPN shares. Cantor Fitzgerald raised their price target on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Wells Fargo & Company lifted their target price on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th.
Read Our Latest Stock Report on Septerna
Institutional Investors Weigh In On Septerna
A hedge fund recently raised its stake in Septerna stock. Woodline Partners LP lifted its holdings in Septerna, Inc. (NASDAQ:SEPN - Free Report) by 94.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 582,585 shares of the company's stock after acquiring an additional 282,585 shares during the quarter. Woodline Partners LP owned approximately 1.31% of Septerna worth $3,373,000 at the end of the most recent reporting period.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Read More
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
